교통이력 데이터의 품질 개선과 What-If 분석을 위한 자료처리 기법의 구현

이민수,정수정,최옥주,맹보연,Lee, Min-Soo,Cheong, Su-Jeong,Choi, Ok-Ju,Meang, Bo-Yeon 한국정보처리학회 2010 정보처리학회논문지D Vol.17 No.2

현재 우리나라에서는 매일 막대한 양의 교통 데이터가 측정장치들로부터 수집되고 있으나 오류 데이터와 누락된 데이터들이 상당히 많은 실정이다. 더구나 이러한 데이터는 중요한 분석의 대상이 될 수 있음에도 불구하고 일정 시간이 지나면 삭제되고 있다. 그리하여 본 논문에서는 이러한 교통 데이터를 지속적으로 누적하여 다차원 모델로 저장하면서 데이터의 품질을 결정하는 유효성과 완전성을 높이면서 what-if 분석 기능을 지원하는 일련의 자료처리 과정을 제공하는 통합 교통이력 데이터베이스 시스템의 구현을 설명한다. 구현된 시스템에서는 다양한 오류 및 누락 데이터 패턴들을 보정하는 기법들을 제공하며, what-if 분석 기능은 다양한 데이터 정제 및 가공 과정들에 관련된 환경변수와 일련의 처리 과정들의 조합을 융통성 있게 정의하도록 함으로써 다양한 상황들을 가정하고 실험하여 결과를 분석할 수 있게 해준다. 이러한 what-if 분석 기능은 교통 데이터의 활용도를 획기적으로 높여주며 외국의 교통데이터 시스템들에서도 제공하지 못하고 있다. 교통이력데이터를 정제한 실험결과 매우 우수한 유효성 및 완전성을 가진 교통 데이터를 생성함을 확인하였다. A vast amount of traffic data is produced every day from detection devices but this data includes a considerable amount of errors and missing values. Moreover, this information is periodically deleted before it could be used as important analysis information. Therefore, this paper discusses the implementation of an integrated traffic history database system that continuously stores the traffic data as a multidimensional model and increases the validity and completeness of the data via a flow of processing steps, and provides a what-if analysis function. The implemented system provides various techniques to correct errors and missing data patterns, and a what-if analysis function that enables the analysis of results under various conditions by allowing the flexible definition of various process related environment variables and combinations of the processing flows. Such what-if analysis functions dramatically increase the usability of traffic data but are not provided by other traffic data systems. Experimantal results for cleaning the traffic history data showed that it provides superior performance in terms of validity and completeness.

정신과에서 분자유전학의 치료적 적용

이민수,Lee, Min Soo 대한생물정신의학회 1998 생물정신의학 Vol.5 No.1

Advances in molecular biology contribute to the understanding genetic mechanism of psychiatric disorders. They have renewed hope for the discovery of disease relevant gene. However, the results somewhat confused. And we will wait for a long time for the application of gene therapy in schizophreniar. Fortunately we could classified the schizophrenia with genotypes of dopamine and serotonin receptors. It is expected that this genetic classification could provide key strategy for the therapeutic application in biological treatment for schizophrenia. The purpose of this article is to call attention of the institute participants to linkage, association, mRNA expression, genotypic classification and to the need for more systemic research. The author summarized the modified methods which were done in his laboratory in appendix.

XML 질의의 수행성능 향상을 위한 트리 구조 XPath 질의의 축약 기법에 관한 연구

이민수,김윤미,송수경,Lee, Min-Soo,Kim, Yun-Mi,Song, Soo-Kyung 한국정보처리학회 2007 정보처리학회논문지D Vol.14 No.6

일반적으로 XML 데이터는 트리 형태의 계층적인 구조를 가지고 있으며, XML 데이터의 저장 및 검색도 이러한 특성을 반영한다. 따라서 XML 데이터를 데이터베이스화 할 때에 XML 엘리먼트 간의 이러한 계층 관계를 반영하여 XML 데이터를 구조화하여 저장하고, 사용자의 검색을 지원하기 위해서는 질의에 명세 된 엘리먼트 구조 간의 계층 관계를 계산하여 처리하는 방법이 필요하다. 구조적 조인(structural joins) 연산은 이 문제의 한 해결책으로서 노드 번호 매기기 방식(node numbering scheme)에 기반한 XML 데이터베이스에 대하여 효율적인 계층 관계 연산 기법을 제시하고 있다. 하지만 계층 관계가 복잡하게 중첩되어 있는 트리 구조의 XML 질의를 처리하려면 여전히 다수의 구조적 조인을 수행해야 하기 때문에 질의 처리 비용이 많이 드는 또 다른 문제를 갖게 된다. 이에 본 논문에서는 선행 연구에서 제안된 트리 구조의 XML 질의 처리시에 필요한 다수의 중첩된 구조적 조인들의 수행비용을 효과적으로 줄이기 위한 사전 처리 방법으로서 동등 클래스 개념을 적용한 정규 표현식(regular expression)으로 된 경로 질의(path query)의 길이를 단축하는 경로식 단축 알고리즘을 소개하며 특히 분기 노드(branch node)가 포함된 경로식 단축 알고리즘을 제안한다. 제안한 알고리즘이 XML 경로식 질의 처리 시간을 평균적으로 1/3로 단축할 수 있음을 실험을 통해서 확인한다. XML data generally consists of a hierarchical tree-structure which is reflected in mechanisms to store and retrieve XML data. Therefore, when storing XML data in the database, the hierarchical relationships among the XML elements are taken into consideration during the restructuring and storing of the XML data. Also, in order to support the search queries from the user, a mechanism is needed to compute the hierarchical relationship between the element structures specified by the query. The structural join operation is one solution to this problem, and is an efficient computation method for hierarchical relationships in an in database based on the node numbering scheme. However, in order to process a tree structured XML query which contains a complex nested hierarchical relationship it still needs to carry out multiple structural joins and results in another problem of having a high query execution cost. Therefore, in this paper we provide a preprocessing mechanism for effectively reducing the cost of multiple nested structural joins by applying the concept of equivalence classes and suggest a query path reduction algorithm to shorten the path query which consists of a regular expression. The mechanism is especially devised to reduce path queries containing branch nodes. The experimental results show that the proposed algorithm can reduce the time requited for processing the path queries to 1/3 of the original execution time.

삼풍 사고 생존자들에서 정신과적 증상의 심각도에 영향을 미치는 요인

이민수,차지현,곽동일,이준상,Lee, Min-Soo,Cha, Ji-Hyun,Kwak, Dong-Il,Lee, Joon-Sang 한국정신신체의학회 1996 정신신체의학 Vol.4 No.2

We studied the factors that would affect the severity of psychiatric symptoms of the Sampoong accident survivors. In this study, the analyzed factors are sex, age, marital status, educational level, loss of consciousness, witness of death, death of related person, duration until the rescue, duration of hospitalization, and psychiatric treatment after the accident. Although our study has some limitations, we found some factors that affect the severity of psychiatric symptoms after the severe traumatic accident.

Tofisopam과 lorazepam의 항불안효과와 안전성에 대한 비교 연구

이민수,김용구,곽동일,Lee, Min Soo,Kim, Yong-Ku,Kwak, Dong-Il 대한생물정신의학회 1997 생물정신의학 Vol.4 No.2

2,3-benzodiazepine계 항불안제인 tofisopam의 항불안 효과 및 안전성을 조사하기 위해 단일맹검 비교연구를 시행하였다. 외래로 내원한 불안 장애 환자 40명을 대상으로 무작위로 tofisopam군과 lorazepam군으로 할당하였으며, 최종 연구를 완결한 환자는 tofisopam군 17명(남자 7명, 여자 10명), lorazepam군은 15명(남자 6명, 여자 9명)이었다. 초기용량으로 tofisopam군은 50mg을 하루 3회 복용하고, lorazepam군은 0.75mg을 하루 2회 복용하도록 하였으며, 임상상태와 부작용에 따라 용량을 임의로 증감하도록 하였고, 일일 최대 용량은 tofisopam군 300mg, lorazepam군 3mg으로 하였다. 임상상태에 대한 평가는 Hamilton rating scale for anxiety(HAM-A)와 Clinical global impression(CGI)으로 하였으며, 약물 투여전과 투여 1주후, 2주후, 4주후에 측정되었다. 결과는 다음과 같다. 1) HAM-A 총점수의 경우, 약물 치료군과 시점을 변인으로 한 two-way repeated-measure ANOVA에서 양군간에 시점에 따른 유의한 차이는 없었다. HAM-A 심리적 불안과 신체적 불안아척도 점수에서 양군간 시점에 따른 유의한 차이는 없었다. 각 군에서 HAM-A 총점수의 시점에 따른 유의한 변화를 나타내었으며, 양군 모두 1주후부터 유의한 감소를 나타내었다. 2) CGI의 질병의 전반적인 심각도에서 약물 치료군과 시점을 변인으로 한 two-way repeated-measure ANOVA에서 양군간에 시점에 따른 유의한 차이는 없었다. 각 군에서 CGI 심각도의 시점에 따른 유의한 변화를 나타내었으며, tofisopam군은 1주후부터 lorazepam군은 4주후부터 유의한 감소를 나타내었다. CGI 호전도에선 각 시점에서"minimally improved"이상을 보인 환자군이 tofisopam군이 94.1%로서 lorazepam군 66.7% 보다 높았다. 3) 안전성 분석에서 각 군에서 생명징후, 혈액학, 생화학, 심전도, 체중에서 유의한 변화를 보이지 않았다. 4) 부작용 면에서 tofisopam군이 lorazepam군보다 각 시점에서 부작용을 호소한 환자수가 적었다. 이상에서 tofisopam은 lorazepam과 유사한 항불안효과를 보였으며, 내약성은 lorazepam에 비해 우수하였다. Objective : A 4-week, single-blind, parallel group study was conducted to evaluate the efficacy and safety of tofisopam and lorazepam in 32 outpatients with anxiety disorder. Methods : Patients were randomized to receive either tofisopam(N=17) or lorazepam(N=15). The starting dose of tofisopam was 50mg t.i.d. daily, which could be increased to a maximum of 100mg t.i.d. according to the patient's clinical response and side effect. The starting dose of lorazepam was 0.75mg b.i.d. daily, which could be increased to a maximum of 1.5mg b.i.d. depending on the patient's clinical response and side effect. Efficacy evaluations at baseline, week 1, 2, and 4 used the 14-item Hamilton Rating Scale for Anxiety(HAM-A) and Clinical Global Impression(CGI). Tolerability was assessed by response to a nonleading question concerning adverse events. Laboratory parameters including vital sign, EKG, hematological, and biochemical values were measured during trial. Results : No significant differences between HAM-A total scores, two HAM-A factors(psychic, somatic) and CGI severity scores were recorded at any point during tofisopam and lorazepam treatments. However, in each group there was a significant decrease in HAM-A total scores, two HAM-A factor s(psychic, somatic), CGI severity scores over time. The pecentages of patients with tofisopam who at least minimally improved increased from 64.7% at week 1 to 94.1% at week 4. The pecentages of patients with lorazepam who at least minimally improved increased from 40.0% at week 1 to 66.7% at week 4. The pecentages of patients with tofisopam who had not any adverse event increased from 58.8% at week 1 to 87.9% at week 4. The pecentages of patients with lorazepam who had not any adverse event were not changed from 46.7% at week 1 to 46.7% at week 4. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial in both groups. Conclusion : These data suggest that tofisopam may be effective in reducing anxiety and is a anti-anxiety drug of identical potency with lorazepam. Tolerability of tofisopam was superior to lorazepam. These findings should be confirmed by using double-blind crossover study with a large member of patients.

Clozapine이 불응성 정신분열증 환자의 혈장 단가아민에 미치는 영향

이민수,김승현,유승호,Lee, Min Soo,Kim, Seung Hyun,Ryu, Seung Ho 대한생물정신의학회 1996 생물정신의학 Vol.3 No.2

It has been known that clozapine is more selective mesolimbic dopamin $D_2$ receptor antagonist and related to 5-HT receptor. In this study, we wxamined the plasma homovanillic acid(HVA), serotonin(5-HT), and 5-hydroxyindoleacetic acid(5-HIM) levels in refractory schizophrenics during clozapine treatment. And we assessed the effects of clozapine on these plasma monoamine metabolites and their association with psychopathology and treatment response. Eight refractory schizophrenic patients(DSM-IV) have entered the study for 3 months during clozapine treatment. Patients were admitted to the inpatient sevice and withdrawn from all neuroleptics for 7-14 days but exceptionally occasional doses of lorazepam was given if needed for behavioral control. The dose of clozapine was titrated as tolerated to 800mg/day. The plasma HVA. 5-HIM and 5-HT levels were measured before treatment and following 2nd week, 4th week, 8th week, and 12th during treatment. Psychopathology was assessed with Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Synrome Scale(PANSS) before and during clozapine treatment. During clozapine treatment, no statistically significant changes were found in plasma HVA, 5-HIM, 5-HT levels, and HVA/5-HIM ratio between baseline and following 2nd week, 4th week, 8th week, 12th week. However, the change in plasma 5-HIAA/5-HT ratio from baseline to 4th week was statistically significant. Generally, changes of plasma HVA, 5-HIAA, 5-HT levels and HVA/5-HIAA ratio were not associated with psychopathology but 5-HIAA was associated with in positive symptoms and general psychopathology of PANSS. These results suggest that clozapine has been found to have relatively weak dopaminergic blokade and stronger serotonergic antagonism.

정신분열병과 $5-HT_{2A}$ / T102C 다형성의 관계

이민수,남종원,곽동일,Lee, Min Soo,Nam, Jong Won,Kwak, Dong Il 대한생물정신의학회 1998 생물정신의학 Vol.5 No.2

The $5-HT_{2A}$ receptor is of great interest for research into schizophrenia and psychopharmacology in light of the observation that schizophrenic patients has 5-HT cortical-subcortical imbalance and atypical antipsychotic clozpine has $5-HT_{2A}$ antagonists properties. An significant association between schizophrenia and the T102C polymorphism of the gene for $5-HT_{2A}$receptor has been reported. In this study, we investigated an association between schizophrenia and the T102C polymorphism of the gene for $5-HT_{2A}$ receptor in Korean schizophrenic patients. The subjects consisted of 139 schizophrenic patients and 88 normal controls. Genomic DNA was amplified by PCR and digested with MsPI. The uncutt product identified allele 1(nucleotide sequence TCT) ; digested products of 216bp and 156bp identified allele 2(nucleotide sequence TCC). The allele frequencies and the genotypic distribution of $5-HT_{2A}$ receptor gene were not significantly different between schizophrenic patients and normal controls. Since allele frequencies of the T102C polymorphism may differ between individuals of different ethnic backgrounds, it needs to be conducted in an advanced research.

세로토닌 재흡수억제제의 약리학과 임상적용

이민수,김표한,Lee, Min-Soo,Kim, Pyo-Han 대한생물정신의학회 1995 생물정신의학 Vol.2 No.2

1) Paroxetine이 5-HT흡수에 가장 강력하고, 선택적이었으며, 그 다음이 fluvoxamine, sertraline, fluoxetine순이었고, sertraline은 다른 SSRIs와는 달리 NE보다 DA억제작용이 더 강했다. 2) Paroxetine이 muscarinic cholinergic 수용체에 대한 친화력이 다소 높았을 뿐, 전반적으로 SSRIs는 histamine $H_1$과 ${\alpha}_1$에 대한 친화력은 약했다. 3) Paroxetine은 ${\beta}$-adrenoceptor와 cyclic AMP에 영향을 미치지 않는 반면, sertraline은 ${\beta}$-adrenoceptor와 cyclic AMP의 감소를 가져왔다. 4) SSRIs의 생체이용율은 대략 50%이었으며, 투약후 2~8시간 사이에 최고혈중농도에 도달하였으며, 특히 sertraline은 음식물과 같이 복용시 혈장의 concentration time curve와 최고 농도를 증가시켰다. 5) Sertraline은 혈중농도가 용량에 비례하였으며, 모든 SSRIs는 비교적 큰 용량분포를 보이고, 높은 비율로 혈장 단백질과 결합되어 있었다. 6) Fluoxetine 대사물의 5-HT 억제 작용이 제일 강했다. 그러나 paroxetine, fluoxetine, sertraline 대사물은 강도는 서로 다르지만 간의 isoenzyme IID6를 억제하며, 그 중에서 paroxetine의 억제작용이 제일 강력하다. 7) Sertraline은 TCAs나 haloperidol과 병합사용시 TCAs나 haloperidol의 혈중농도의 유의한 변화가 없었으며, MAOI A형인 moclobemide와 비교적 안전하게 병용 치료할 수 있다. 8) SSRIs는 TCAs와 비교해볼 때 치료효과는 유사하였으나 fluvoxamine은 자살사고에, paroxetine은 우울중에서 나타나는 불안과 운동성 초조증에 효과적이다. 9) 급성 우울증 삽화시 현저한 효과를 보인 후 적어도 4개월 이상의 유지치료기간이 필요하다. 10) SSRIs는 위장관계통의 부작용이 가장 많았고, 부작용은 일반적으로 분복한 경우가 적었다. In comparison with tricyclic antidepressants(TCAs), one of the most interesting characteristics of selective serotonin reuptake inhibitors(SSRIs) is its structural differences, reveals different pharmacological properties. The applications at the moment are most effective in clinical applications to depression. The limited result of the research to date on the various applications of SSRIs has not revealed the total potential and applicability of SSRIs. Therefore, attending physicians utilizing SSRIs do not know the full capabilities of the drug on patients and what the patients may reap in terms of benefit from its curing elements. Physicians must first try to understand the full potential of SSRIs and its potential applications for it to be effective on patients. recently, it has been determined that SSRIs and other drugs when administered together may be more effective in the healing process because SSRIs complements and aids in the enhancement and effect of the other drugs. This article is written to give attention to the reader of the pharmacological properties and the clinical use of SSRIs. It is the authors's hope that continuous research on the particular aspects of SSRIs can aid the clinicians in the use of this SSRIs.

기분부전장애에서 Moclobemide와 Amitriptyline의 치료 효과와 내약성 비교 연구

이민수,남종원,유승호,차지현,김용구,Lee, Min Soo,Nam, Jong Won,Ryu, Seung Ho,Cha, Ji Hyun,Kim, Yong Ku 대한생물정신의학회 1999 생물정신의학 Vol.6 No.1

Background : Since dysthymia begins in late childhood or adolescence and has a chronic course, long-term pharmacotherapy may be required. New generation antidepressant, moclobemide, with more acceptable side effect profiles, is effective in the treatment of dysthymia. The main objective of this study was to determine whether they exhibit comparable efficacy and tolerability in dysthymia to amitriptyline. Method and Materials : The efficacy and tolerability of the moclobemide and amitriptyline, were compared in a eight-week single-centre double-blind study in patients(n=37) with dysthymia using he HAMD-17, the Clinical Global Impression Scale(CGI), the Montgomery-Asberg Depression Rating Scale (MADRS), Efficacy Index-Therapeutic Index(EITE), 4-point Index Side Effect Scale(4-PISES), and Efficacy Index- Side Effect Scale(EISE). Results : A total of 37 patients entered the study, 19 were randomly assigned to the moclobemide group and 18 to be amitriptyline group. Demo-graphic and illness characteristics were similar in both groups. There were no significant difference between two groups at the total 17-HDRS score, the HAMD-17% improvement, the total MADRS score, CGI response, and the EITE. In the comparison of EISE between two groups, the scores of the moclobemide group were relatively lower than the amitriptylinen group in full treatment. And the differences were significant(moclobemide group $1.39{\pm}0.61$ ; amitriptyline group $2.00{\pm}0.85$, p<.001). At the 4-PISE, There was no serious or treatment threatening side effects. And there was no specific difference in side effects between two groups. The moclobemide group reported higher EIR scores than the amitriptyline group at every follow up day, but the differences were not significant. And, there was no significant differences in the scores of five HRQOL subcategories which is compared between two groups at every follow up days. Conclusions : In terms of 17-HDRS and MADRS, moclobemide and amitriptyline are equally effective at least in allevating dysthymic symptoms. But moclobemide tended to be less troubling and better tolerated than amitriptyline. Therefore, moclobemide treatment can be used as a safe, and higher satisfactory treatment strategy for the dysthymia.

내외과계 환자의 정신과 약물치료에서 약물-약물 상호작용 - 고려대학교 부속병원의 자문조정의 경험을 통하여 -

이민수,이헌정,Lee, Min Soo,Lee, Heon-Jeong 대한생물정신의학회 1999 생물정신의학 Vol.6 No.1

Polypharmacotherapy, both psychotropic and nonpsychotropic, is widespread in various situations including psychiatric hospitals and general hospitals. As the clinical practice of using more than one drug at a time increase, the clinician is faced with ever-increasing number of potential drug interactions. Although many interactions have little clinical significances, some may interfere with treatment or even be life-threatening. The objective of this review is evaluation for drug-drug interactions often encountered in psychiatric consultation. Drug interactions can be grouped into two principal subdivisions : pharmacokinetic and pharmacodynamic. These subgroups serve to focus attention on possible sites of interaction as a drug moves from the site of administration and absorption to its site of action. Pharmacokinetic processes are those that include transport to and from the receptor site and consist of absorption, distribution on body tissue, plasma protein binding, metabolism, and excretion. Pharmacodynamic interactions occur at biologically active sites. In psychiatric consultation, these two subdivisions of drug interactions between psychotropic drugs and other drugs are likely to happen. We gathered informations of the drugs used in physically ill patients who are consulted to psychiatric department in Korea University Hospital. And we reviewed the related literatures about the drug-drug interactions between psychotropic drugs and other drugs.